Allergy Diagnostics & Therapeutics Market To Reach $78.0 Billion By 2033

Allergy Diagnostics & Therapeutics Market Growth & Trends

The global allergy diagnostics & therapeutics market size is estimated to reach USD 78.0 billion by 2033, registering a CAGR of 9.95% from 2026 to 2033, according to a new report by Grand View Research, Inc. Increasing incidences of allergic diseases, coupled with demand for advanced therapeutics, is expected to drive the market growth in the coming years. According to estimates published by the American Academy of Allergy Asthma & Immunology (AAAAI), allergic rhinitis affects approximately 10-30% of the global population, thereby impacting the adoption of allergy therapeutics globally.

The increasing integration of technologically advanced products, such as the use of artificial intelligence technology to advance treatment outcomes and manage diseases, helps practitioners in the decision-making process. Furthermore, the rising adoption of mHealth apps for diagnosing allergies such as rhinitis is expected to boost the market. For instance, the MASK-Air app is dedicated specifically to allergic rhinitis.

Monoclonal antibodies are anticipated to contribute to the development of new therapies that eradicate specific allergy concerns, owing to their higher efficacy, long-term tolerability, and safety. Hence, key companies are developing novel & effective biologic-based therapies designed with target-specific mechanisms directed toward selective targets, especially monoclonal antibodies. In addition, consistent product approvals of highly significant monoclonal antibodies for allergy disorders are anticipated to expand the scope for growth. 

New therapies such as anti-immunoglobulin E (IgE) antibodies, cytokine modulators, and DNA vaccinations are being used to treat allergic disorders. Omalizumab is a recombinant humanized IgG1 monoclonal anti-IgE antibody, which is used for treating allergic chronic urticaria and asthma. In April 2021, Genentech (Roche Group) announced that its prefilled syringe for self-injection has received FDA approval for Xolair (omalizumab) in the U.S. for chronic idiopathic urticaria allergic asthma, and nasal polyps.

The allergy diagnostics & therapeutics market is moderately competitive, with a strong presence of notable companies such as Merck & Co., Inc, Thermo Fisher Scientific, Inc., Abbott, and Pfizer, Inc. These players are undertaking various initiatives to increase their capabilities, expand their product portfolios, and improve their competencies. 

 Request a free sample copy or view report summary: Allergy Diagnostics And Therapeutics Market Report

Allergy Diagnostics & Therapeutics Market Report Highlights

• In terms of type, the therapeutics segment accounted for the largest revenue share of over 82.86% in 2025 due to their focus on treating allergic conditions.

• In terms of allergen type, the inhaled allergies segment held the largest revenue share of over 49.86% in 2025, owing to the growing incidence of respiratory allergies caused by industrialization and increasing air pollution.

• In terms of test type, the in vitro test accounted for the largest market share of 52.30% in 2025. New diagnostic technologies are revolutionizing the field by enabling real-time, highly sensitive detection and personalized risk evaluations.

• The North America allergy diagnostics and therapeutics market is the leading region with a revenue share of 36.62% in 2025, owing to its strong healthcare infrastructure, tight regulatory frameworks, and high prevalence of allergic illnesses.

Allergy Diagnostics & Therapeutics Market Segmentation

Grand View Research has segmented the global allergy diagnostics and therapeutics market based on type, allergen type, test type, and region:

Allergy Diagnostics & Therapeutics Type Outlook (Revenue, USD Million, 2021 - 2033)

• Diagnostics

  • Instruments

  • Consumables

  • Services

• Therapeutics

  • Antihistamines

  • Decongestants

  • Corticosteroids

  • Mast Cell Stabilizers

  • Leukotriene Inhibitors

  • Nasal Anti-cholinergic

  • Immuno-modulators

  • Epinephrine

  • Immunotherapy

Allergy Diagnostics & Therapeutics Allergen Type Outlook (Revenue, USD Million, 2021 - 2033)

• Food

  • Dairy Products

  • Poultry Product

  • Tree Nuts

  • Peanuts

  • Shellfish

  • Wheat

  • Soy

  • Other Food Allergens

• Inhaled

• Drug

• Other allergen types

Allergy Diagnostics & Therapeutics Test Type Outlook (Revenue, USD Million, 2021 - 2033)

• In Vivo Tests

  • Skin Prick Test

  • Intradermal Test

  • Patch Test

• In Vitro Tests

Allergy Diagnostics & Therapeutics Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Allergy Diagnostics & Therapeutics Market

• R-Biopharm AG

• Thermo Fisher Scientific, Inc.

• DASIT Group SPA

• EUROIMMUN Medizinische Labordiagnostika AG (PerkinElmer, Inc.)

• AESKU.GROUP GmbH

• bioMérieux

• Siemens Healthcare GmbH

• Stallergenes Greer

• HYCOR Biomedical

• Minaris Medical America, Inc.

• Omega Diagnostics Group PLC

• Lincoln Diagnostics, Inc.

• HOB Biotech Group Corp., Ltd.

• Danaher

• Alcon

• AbbVie, Inc.

• Sanofi

• Allergy Therapeutics

• Pfizer, Inc.

• Teva Pharmaceutical Industries Ltd.

• GSK plc

• Sun Pharmaceutical Industries Ltd

• F. Hoffmann-La Roche Ltd.

• Merck & Co., Inc.

• Astellas Pharma Inc.

• Epigenomics AG